Knol Wilma, Verduijn Monique M, Lelie-van der Zande A C A M Rian, van Marum Rob J, Brouwers J R B J Koos, van der Cammen Tischa J M, Petrovic Mirko, Jansen Paul A F
UMC Utrecht, afd. Geriatrie en Expertisecentrum Pharmacotherapie bij Ouderen (Ephor), Utrecht.
Ned Tijdschr Geneeskd. 2015;159:A8904.
The use of potentially inappropriate medications (PIMs) by older people and potential prescribing omissions (PPOs) represent a serious problem. It increases the risk of adverse drug reactions (ADRs), however it is susceptible to influence in a substantial number of cases. Use of the STOPP/START criteria developed in Ireland to optimise pharmacotherapy of older people reduces the number of ADRs and medication errors. Licensing of new drugs, the increased number of potentially inappropriate drugs, and the availability of new literature were grounds for an update of the first version of the STOPP/START criteria which was published in 2008. In order to develop a screening tool with a broader application, a consensus panel of experts in the field of pharmacotherapy of older people was selected from 14 European countries for the second version of the STOPP/START criteria, including two from the Netherlands. The translation of the second version of the STOPP/START criteria has been adapted to the situation in the Netherlands, partly by omitting drugs that are not licensed in the Netherlands.
老年人使用潜在不适当药物（PIMs）和潜在处方遗漏（PPOs）是一个严重问题。这会增加药物不良反应（ADR）的风险，不过在很多情况下它容易受到影响。使用爱尔兰制定的STOPP/START标准来优化老年人药物治疗可减少ADR和用药错误的数量。新药许可、潜在不适当药物数量的增加以及新文献的可得性是对2008年发布的第一版STOPP/START标准进行更新的依据。为了开发一种应用更广泛的筛查工具，从14个欧洲国家挑选了老年药物治疗领域的专家组成共识小组来制定第二版STOPP/START标准，其中包括两名来自荷兰的专家。第二版STOPP/START标准的翻译已根据荷兰的情况进行了调整，部分是通过剔除在荷兰未获许可的药物来实现的。
